

SPECIAL FEATURES

Highlights of This Issue 3231

CCR Translations

- 3233** Biomarker Discovery from We to Me: Is Learning from Each Patient a New Approach?



Stephanie Lheureux

See related article, p. 3282

- 3236** The Long Neglected Player: Modeling Tumor Uptake to Guide Optimal Dosing

Leire Ruiz-Cerdá, Eduardo Asín-Prieto, Zinnia P. Parra-Guillen, and Iñaki F. Trocóniz

See related article, p. 3325

- 3239** Antigen Presentation Keeps Trending in Immunotherapy Resistance

Anusha Kalbasi and Antoni Ribas

See related article, p. 3366

CCR Drug Updates

- 3242** FDA Approval: Gemtuzumab Ozogamicin for the Treatment of Adults with Newly Diagnosed CD33-Positive Acute Myeloid Leukemia

Emily Y. Jen, Chia-Wen Ko, Jee Eun Lee, Pedro L. Del Valle, Antonina Aydanian, Charles Jewell, Kelly J. Norsworthy, Donna Przepiorcka, Lei Nie, Jiang Liu, Christopher M. Sheth, Marjorie Shapiro, Ann T. Farrell, and Richard Pazdur

CLINICAL TRIAL BRIEF REPORT

- 3247** Prospective Clinical Trial of Ixazomib, Dexamethasone, and Rituximab as Primary Therapy in Waldenström Macroglobulinemia

Jorge J. Castillo, Kirsten Meid, Joshua N. Gustine, Toni Dubeau, Patricia Severns, Zachary R. Hunter, Guang Yang, Lian Xu, and Steven P. Treon

CLINICAL TRIALS: TARGETED THERAPY

- 3253** A First-in-Human Phase 1 Study of LY3023414, an Oral PI3K/mTOR Dual Inhibitor, in Patients with Advanced Cancer



Johanna C. Bendell, Anna M. Varghese, David M. Hyman, Todd M. Bauer, Shubham Pant, Sophie Callies, Ji Lin, Ricardo Martinez, Enaksha Wickremsinhe, Aaron Fink, Volker Wacheck, and Kathleen N. Moore

- 3263** Evaluation of Prexasertib, a Checkpoint Kinase 1 Inhibitor, in a Phase Ib Study of Patients with Squamous Cell Carcinoma



David S. Hong, Kathleen Moore, Manish Patel, Stefan C. Grant, Howard A. Burris III, William N. William Jr, Suzanne Jones, Funda Meric-Bernstam, Jeffrey Infante, Lisa Golden, Wei Zhang, Ricardo Martinez, Sameera Wijayawardana, Richard Beckmann, Aimee Bence Lin, Cathy Eng, and Johanna Bendell

- 3273** Complete and Durable Responses in Primary Central Nervous System Posttransplant Lymphoproliferative Disorder with Zidovudine, Ganciclovir, Rituximab, and Dexamethasone

James P. Dugan, Bradley M. Haverkos, Lynda Villagomez, Ludmila K. Martin, Mark Lustberg, John Patton, Marisa Martin, Ying Huang, Gerard Nuovo, Fengting Yan, Robert Cavaliere, Joyce Fingerth, Shannon C. Kenney, Richard F. Ambinder, Gerard Lozanski, Pierluigi Porcu, Michael A. Caligiuri, and Robert A. Baiocchi

CLINICAL TRIALS: IMMUNOTHERAPY

- 3282** Exceptional Response to Pembrolizumab in a Metastatic, Chemotherapy/Radiation-Resistant Ovarian Cancer Patient Harboring a PD-L1-Genetic Rearrangement

Stefania Bellone, Natalia Buza, Jungmin Choi, Luca Zammataro, Laurie Gay, Julia Elvin, David L. Rimm, Yuting Liu, Elena S. Ratner, Peter E. Schwartz, and Alessandro D. Santin

See related commentary, p. 3233

- 3292** A Model of Overall Survival Predicts Treatment Outcomes with Atezolizumab versus Chemotherapy in Non–Small Cell Lung Cancer Based on Early Tumor Kinetics

Laurent Claret, Jin Y. Jin, Charles Ferte, Helen Winter, Sandhya Girish, Mark Stroh, Pei He, Marcus Ballinger, Alan Sandler, Amita Joshi, Achim Rittmeyer, David Gandara, Jean-Charles Soria, and René Bruno

Table of Contents

PRECISION MEDICINE AND IMAGING

- 3299** Prevalent Homozygous Deletions of Type I Interferon and Defensin Genes in Human Cancers Associate with Immunotherapy Resistance
Zhenqing Ye, Haidong Dong, Ying Li, Tao Ma, Haojie Huang, Hon Sing Leong, Jeanette Eckel-Passow, Jean-Pierre A. Kocher, Han Liang, and Liguang Wang
- 3309** A Gallium-67/68–Labeled Antibody Fragment for Immuno-SPECT/PET Shows Low Renal Radioactivity Without Loss of Tumor Uptake
Tomoya Uehara, Miki Yokoyama, Hiroyuki Suzuki, Hirofumi Hanaoka, and Yasushi Arano
- 3317** Cell-Free DNA Modification Dynamics in Abiraterone Acetate-Treated Prostate Cancer Patients
Juožas Gordevičius, Algimantas Kriščiūnas, Daniel E. Groot, Steven M. Yip, Miki Susic, Andrew Kwan, Rafal Kustra, Anthony M. Joshua, Kim N. Chi, Art Petronis, and Gabriel Oh
- 3325** Prediction of the Optimal Dosing Regimen Using a Mathematical Model of Tumor Uptake for Immunocytokine-Based Cancer Immunotherapy
Benjamin Ribba, Christophe Boetsch, Tapan Nayak, Hans Peter Grimm, Jehad Charo, Stefan Evers, Christian Klein, Jean Tessier, Jean Eric Charoin, Alex Phipps, Pavel Pisa, and Volker Teichgräber
See related commentary, p. 3236
- 3334** Resistance Mechanisms to Targeted Therapies in $ROS1^+$ and ALK^+ Non–small Cell Lung Cancer
Caroline E. McCoach, Anh T. Le, Katherine Gowan, Kenneth Jones, Laura Schubert, Andrea Doak, Adriana Estrada-Bernal, Kurtis D. Davies, Daniel T. Merrick, Paul A. Bunn Jr, W. Tom Purcell, Rafal Dziadziszczko, Marileila Varella-Garcia, Dara L. Aisner, D. Ross Camidge, and Robert C. Doebele
- 3348** Change in Topoisomerase 1–Positive Circulating Tumor Cells Affects Overall Survival in Patients with Advanced Breast Cancer after Treatment with Etirinotecan Pegol
Hope S. Rugo, Javier Cortes, Ahmad Awada, Joyce O’Shaughnessy, Chris Twelves, Seock-Ah Im, Alison Hannah, Lin Lu, Sherwin Sy, Katie Caygill, Deborah A. Zajchowski, Darren W. Davis, Mary Tagliaferri, Ute Hoch, and Edith A. Perez
- 3358** Risk Assessment after Neoadjuvant Chemotherapy in Luminal Breast Cancer Using a Clinicomolecular Predictor
Sibylle Loibl, Karsten Weber, Jens Huober, Kristin Krappmann, Frederik Marmé, Christian Schem, Knut Engels, Berit Maria Pfitzner, Sherko Kümmel, Jenny Furlanetto, Arndt Hartmann, Silvia Darb-Esfahani, Volkmar Müller, Annette Staebler, Gunter von Minckwitz, Ralf Kronenwett, and Carsten Denkert

TRANSLATIONAL CANCER MECHANISMS AND THERAPY

- 3366** The RNA-binding Protein MEX3B Mediates Resistance to Cancer Immunotherapy by Downregulating HLA-A Expression
Lu Huang, Shruti Malu, Jodi A. McKenzie, Miles C. Andrews, Amjad H. Talukder, Trang Tieu, Tatiana Karpinets, Cara Haymaker, Marie-Andrée Forget, Leila J. Williams, Zhe Wang, Rina M. Mbofung, Zhi-Qiang Wang, Richard Eric Davis, Roger S. Lo, Jennifer A. Wargo, Michael A. Davies, Chantale Bernatchez, Timothy Heffernan, Rodabe N. Amaria, Anil Korkut, Weiyi Peng, Jason Roszik, Gregory Lizée, Scott E. Woodman, and Patrick Hwu
See related commentary, p. 3239
- 3377** BRAF and MEK Inhibitors Increase PD-1-Positive Melanoma Cells Leading to a Potential Lymphocyte-Independent Synergism with Anti-PD-1 Antibody
Martina Sanlorenzo, Igor Vujic, Arianna Floris, Mauro Novelli, Loretta Gammaitoni, Lidia Giraud, Marco Macagno, Valeria Leuci, Ramona Rotolo, Chiara Donini, Marco Basiricò, Pietro Quaglino, Maria Teresa Fierro, Silvia Giordano, Maria Sibilia, Fabrizio Carnevale-Schianca, Massimo Aglietta, and Dario Sangiolo
- 3386** Targeting the Leukemia Antigen PR1 with Immunotherapy for the Treatment of Multiple Myeloma
Gheath Alatrash, Alexander A. Perakis, Celine Kerros, Haley L. Peters, Pariya Sukhumalchandra, Mao Zhang, Haroon Jakher, Madhushree Zope, Rebecca Patenia, Anna Sergeeva, Shuhua Yi, Ken H. Young, Anne V. Philips, Amanda M. Cernosek, Haven R. Garber, Na Qiao, Jinsheng Weng, Lisa S. St John, Sijie Lu, Karen Clise-Dwyer, Elizabeth A. Mittendorf, Qing Ma, and Jeffrey J. Mouldrem
- 3397** Interferon-Stimulated Genes Are Involved in Cross-resistance to Radiotherapy in Tamoxifen-Resistant Breast Cancer
Annemarie E.M. Post, Marcel Smid, Anika Nagelkerke, John W.M. Martens, Johan Bussink, Fred C.G.J. Sweep, and Paul N. Span
- 3409** Combinatorial Effects of VEGFR Kinase Inhibitor Axitinib and Oncolytic Virotherapy in Mouse and Human Glioblastoma Stem-Like Cell Models
Dipongkor Saha, Hiroaki Wakimoto, Cole W. Peters, Sławomir J. Antoszczyk, Samuel D. Rabkin, and Robert L. Martuza

Table of Contents

3423 Targeting NAD⁺/PARP DNA Repair Pathway as a Novel Therapeutic Approach to *SDHB*-Mutated Cluster I Pheochromocytoma and Paranglioma
Ying Pang, Yanxin Lu, Veronika Caisova, Yang Liu, Petra Bullova, Thanh-Truc Huynh, Yiqiang Zhou, Di Yu, Zdenek Frysak, Igor Hartmann, David Taïeb, Karel Pacak, and Chunzhang Yang

3433 Discovery of a Glucocorticoid Receptor (GR) Activity Signature Using Selective GR Antagonism in ER-Negative Breast Cancer
Diana C. West, Masha Kocherginsky, Eva Y. Tonsing-Carter, D. Nesli Dolcen, David J. Hosfield, Ricardo R. Lastra, Jason P. Sinnwell, Kevin J. Thompson, Kathleen R. Bowie, Ryan V. Harkless, Maxwell N. Skor, Charles F. Pierce, Sarah C. Styke, Caroline R. Kim, Larischa de Wet, Geoffrey L. Greene, Judy C. Boughey, Matthew P. Goetz, Krishna R. Kalari, Liewei Wang, Gini F. Fleming, Balázs Györfy, and Suzanne D. Conzen

3447 A Survey on Data Reproducibility and the Effect of Publication Process on the Ethical Reporting of Laboratory Research
Delphine R. Boulbes, Tracy Costello, Keith Baggerly, Fan Fan, Rui Wang, Rajat Bhattacharya, Xiangcang Ye, and Lee M. Ellis

3456 Identification and Validation of a 3-Gene Methylation Classifier for HPV-Based Cervical Screening on Self-Samples
Wina Verlaat, Barbara C. Snoek, Daniëlle A.M. Heideman, Saskia M. Wiling, Peter J.F. Snijders, Putri W. Novianti, Annina P. van Splunter, Carel F.W. Peeters, Nienke E. van Trommel, Leon F.A.G. Massuger, Ruud L.M. Bekkers, Willem J.G. Melchers, Folkert J. van Kemenade, Johannes Berkhof, Mark A. van de Wiel, Chris J.L.M. Meijer, and Renske D.M. Steenbergen


3465 Mechanistic Insights of an Immunological Adverse Event Induced by an Anti-KIT Antibody Drug Conjugate and Mitigation Strategies
Lawrence L'Italien, Olivia Orozco, Tinya Abrams, Lisa Cantagallo, Anu Connor, Jayesh Desai, Hilmar Ebersbach, Hans Gelderblom, Keith Hoffmaster, Emma Lees, Heiko Maacke, Siew Schleyer, Darko Skegro, and Si Tuen Lee-Hoeflich

 AC icon indicates AuthorChoice

For more information please visit www.aacrjournals.org

ABOUT THE COVER

The cover shows an ovarian cancer tissue section from a patient harboring a rare PD-L1 tumor genetic rearrangement. Immunofluorescence multiplex imaging demonstrates strong colocalization of PD-L1 and cytokeratin in the tumor cells with negative PD-L1 expression in infiltrating CD68⁺ macrophages. PD-L1 (red)/cytokeratin (green)/DAPI (blue)/CD68 (magenta). For details, see the article by Bellone and colleagues on page 3282 of this issue.



Clinical Cancer Research

24 (14)

Clin Cancer Res 2018;24:3231-3474.

Updated version Access the most recent version of this article at:
<http://clincancerres.aacrjournals.org/content/24/14>

E-mail alerts [Sign up to receive free email-alerts](#) related to this article or journal.

Reprints and Subscriptions To order reprints of this article or to subscribe to the journal, contact the AACR Publications Department at pubs@aacr.org.

Permissions To request permission to re-use all or part of this article, use this link <http://clincancerres.aacrjournals.org/content/24/14>. Click on "Request Permissions" which will take you to the Copyright Clearance Center's (CCC) Rightslink site.